Aarti Drugs Ltd vs Ambalal Sarabhai Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Aarti Drugs Ltd is ₹ 372.8 as of 12 Jun 15:30 . The P/E Ratio of Aarti Drugs Ltd changed from 23.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of -4.34% over 5 yearsThe P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 years The Market Cap of Aarti Drugs Ltd changed from ₹ 6475 crore on March 2021 to ₹ 3123 crore on March 2025 . This represents a CAGR of -13.57% over 5 yearsThe Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 years The revenue of Aarti Drugs Ltd for the Mar '26 is ₹ 721.06 crore as compare to the Dec '25 revenue of ₹ 602.94 crore. This represent the growth of 19.59% The revenue of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 68.51 crore as compare to the Dec '25 revenue of ₹ 54.76 crore. This represent the growth of 25.11% The ebitda of Aarti Drugs Ltd for the Mar '26 is ₹ 96.56 crore as compare to the Dec '25 ebitda of ₹ 56.26 crore. This represent the growth of 71.63% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 8.72 crore as compare to the Dec '25 ebitda of ₹ 6.02 crore. This represent the growth of 44.85% The net profit of Aarti Drugs Ltd changed from ₹ 33.27 crore to ₹ 55.26 crore over 8 quarters. This represents a CAGR of 28.88% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 6.5 crore over 8 quarters. This represents a CAGR of 330.95% The Dividend Payout of Aarti Drugs Ltd changed from 9.04 % on March 2021 to 5.8 % on March 2025 . This represents a CAGR of -8.49% over 5 yearsThe Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aarti Drugs Ltd

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

FAQs for the comparison of Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Ambalal Sarabhai Enterprises Ltd?

Market cap of Aarti Drugs Ltd is 3,402 Cr while Market cap of Ambalal Sarabhai Enterprises Ltd is 248 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd?

The stock performance of Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd?

As of June 15, 2026, the Aarti Drugs Ltd stock price is INR ₹372.8. On the other hand, Ambalal Sarabhai Enterprises Ltd stock price is INR ₹32.4.

How do dividend payouts of Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Ambalal Sarabhai Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.